We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.


Refine your search

Content type
Firm name

190 results found


Reed Smith LLP | USA | 5 May 2011

California Senate committee passes broad online privacy bill

The Judiciary Committee of the California State Senate on Tuesday passed SB761, legislation that would broadly regulate all online data collection and impose a "do not track" regulatory regime for online behavioral advertising.


Sheppard Mullin Richter & Hampton LLP | USA | 29 Jun 2009

Reverse payment issue continues to sizzle

We reported recently that the issue of reverse settlement payments to generic drug manufacturers was continuing to heat up this summer.


McDermott Will & Emery | USA | 11 Feb 2009

Proposed legislation prohibits settlement payments to generic drug manufacturers

The U.S. Senate Judiciary Committee is considering legislation that, if passed, would amend the Clayton Act to “make illegal anti-competitive, anti-consumer patent payoffs in which brand name drug companies pay generic manufacturers millions of dollars to keep generic competition off the market.”


Jorden Burt LLP | USA | 15 Oct 2008

Senate seeks additional protection for senior investors

Federal and state regulators have had their say and now Congress may be stepping in to adopt measures aimed at eliminating investment fraud against seniors.


Hogan Lovells | USA | 2 May 2007

Hill roundup: new Congress, same bills

In Issue 4, page 12, we discussed several legislative initiatives that were introduced during the last Congress which, according to their sponsors, were aimed at preserving or enhancing competition in the pharmaceutical industry.


Bird & Bird LLP | USA | 9 Mar 2007

The end of reverse premium settlements in generic pharmaceutical litigation

On 15 February 2007, the Senate Judiciary Committee unanimously passed a bill, the “Preserve Access to Affordable Generics Act”, that would prohibit brand drug manufacturers from using out-of-court settlements known as reverse payments to delay generic entry into the market.

Previous page 1 2 3 ...